Search

Displaying results 2301 - 2310 of 10000 in total
  1. Drug

    Cidofovir

    go.drugbank.com/drugs/DB00369
    ApprovedInvestigational

    Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. … [FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]

  2. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    [A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … including atopic dermatitis, a chronic inflammatory skin disease with complex pathogenesis.

  3. Drug

    Human cytomegalovirus immune globulin

    go.drugbank.com/drugs/DB13886
    ApprovedInvestigational

    The seroprevalence of antibodies in adults ranges from 40-100 % with an inverse correlation to socioeconomic status. … During the span of an individual's life, the virus may reactivate, resulting in repeated shedding and spread of the virus.

  4. Drug

    Vorinostat

    go.drugbank.com/drugs/DB02546
    ApprovedInvestigational

    A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier … It is the first in a new class of agents known as histone deacetylase inhibitors.

  5. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral … production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in

  6. Drug

    Fencamfamin

    go.drugbank.com/drugs/DB01463
    ApprovedIllicitWithdrawn

    Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant. … It is especially useful in patients with chronic conditions due to its favourable safety profile.

  7. Drug

    Toremifene

    go.drugbank.com/drugs/DB00539
    ApprovedInvestigational

    [A256928] Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however … , it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.

  8. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    In April 2018, the U.S. … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].

  9. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction

  10. Drug

    Inosine

    go.drugbank.com/drugs/DB04335
    Approved

    (Dorland, 28th ed) … It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules.